Quantum Blue®
anti-TNFα Drug Monitoring
The BÜHLMANN Quantum Blue® Therapeutic Drug Monitoring assays are the first rapid tests to measure trough level in patient’s serum allowing timely decision making for dose adjustments before the next treatment.
The technology offers rapid and reliable applications for therapeutic drug monitoring (TDM) of anti-inflammatory biologics, thus providing powerful tools for immediate decision making in patient's treatment management.
Applications
The following Quantum Blue® assays for therapeutic drug monitoring are currently available.
Quantum Blue® Adalimumab
The biologic drug Adalimumab is a therapeutic monoclonal antibody. It acts as an antagonist to TNF alpha, thus effectively blocks the inflammatory process in numerous chronic inflammatory diseases like Crohn’s disease, ulcerative colitis and inflammatory arthritis.
Quantum Blue® Anti-Adalimumab (RUO)
The presence of anti-drug antibodies (ADA) against adalimumab can diminish the clinically beneficial effect of the drug. The Quantum Blue® Anti-Adalimumab rapid test allows for a highly sensitive detection of antibodies against adalimumab within
15 minutes.
Quantum Blue® Infliximab
The biologic drug Infliximab is a therapeutic monoclonal antibody. It acts as an antagonist to TNF alpha, thus effectively blocks the inflammatory process in numerous chronic inflammatory diseases like Crohn’s disease, ulcerative colitis and inflammatory arthritis.
Quantum Blue® Anti-Infliximab
The presence of anti-drug antibodies (ADA) against infliximab can diminish the clinically beneficial effect of the drug. The Quantum Blue® Anti-Infliximab rapid test allows for a highly specific detection of antibodies against infliximab within 15 min.
Benefits
Quantitative range:
- Infliximab: 0.4 - 20μg/ml - Linear up to 180μg/ml
- Adalimumab: 1.3 - 35μg/mlSingle use assay: - No need to batch samples - Individually packaged test
Assay time of 15 minutes
Excellent correlation with established ELISA methods
Control included on each cassette
Read using a simple bench top reader
Videos
-
Quantitative trough level measurement for therapeutic drug monitoring using the Quantum Blue® TDM rapid test technology.
-
Therapeutic Drug Monitoring in Daily Practice with Prof. Rogério S. Parra at GEDII 2020
-
"Meeting the Experts" in the field of TDM in IBD at the GEDII 2020 Annual Meeting
-
TDM Success Story from convent hospital Barmherzige Brüder St. Veit
-
New biosimilar of infliximab SB2 can be quantified by IXF-optimized therapeutic drug monitoring
-
Using point of care testing for infliximab and fecal calprotectin in IBD patients with secondary LOR
-
Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO)
-
Point-of-care infliximab quantification in inflammatory bowel disease in daily practice
Case Studies
-
High Correlation of the Quantum Blue® rapid assay with HPLC mass spectrometry for infliximab.......
Olson, et al (2020)
Poster from UEG Virtual Week 202023/04/21 Download: 7.00KB -
First successful comparison of Quantum Blue® rapid TDM assay standardization .......
Keller, et al (2020)
Poster from UEG Virtual Week 202026/04/21 Download: 8.21KB
